Back to Results

Daxor Corporation (DXR)

Daxor Corporation is a healthcare equipment and supplies company whose common stock is listed on the NASDAQ under the symbol DXR. The company focuses on medical instrumentation and biotechnology, with development centered on the BVA-100 Blood Volume Analyzer, a device used to measure human blood volume, together with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. Originally incorporated in 1971, the company adopted the Daxor name in May 1973 and is based in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of the Estate of Joseph Feldschuh.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-DXR
$13.46
19.8% Upside
Undervalued
$20
78.1% Upside
Bargain
Good
0.0%
November 12, 2026
10.5x
1.3x
2,090.7x
65.563 M
14.038 M
0.0%
49.7%
1,684.1
-131.3%
Valuation • Fair Value

Daxor Corporation (NASDAQ-DXR) Fair Value by Valuation Model

Review the available estimates for Daxor Corporation (NASDAQ-DXR), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$13.46

Estimated upside of 19.8% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$19.64

Discounted cash flow valuation reference.

Ben Graham Formula Value

$11.84

Classic Ben Graham valuation formula reference.

EPV Fair Value

$8.93

Earnings power value estimate.

Comps Fair Value

$11.89

Comparable-company valuation reference.

Analyst Price Target

$20

Analysts imply upside of 78.1%.

How to read these valuation models

Use the 7 available valuation references for Daxor Corporation (NASDAQ-DXR) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Daxor Corporation (NASDAQ-DXR)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

31.36 K

Current operating scale indicator.

Revenue Forecast

9.3 M

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Daxor Corporation (NASDAQ-DXR) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Daxor Corporation (NASDAQ-DXR)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Altman Z-Score

1,684.1

Relatively strong balance-sheet zone.

FCF / Net Income

-131.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Daxor Corporation (NASDAQ-DXR). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Daxor Corporation (NASDAQ-DXR)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 12, 2026

Days to Earnings

51

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Daxor Corporation (NASDAQ-DXR), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Daxor Corporation (NASDAQ-DXR) Stock Forecast & Technical Outlook

Review Daxor Corporation (NASDAQ-DXR) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Daxor Corporation (NASDAQ-DXR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Daxor Corporation (NASDAQ-DXR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Daxor Corporation (NASDAQ-DXR) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Daxor Corporation (NASDAQ-DXR) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Daxor Corporation (NASDAQ-DXR) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Daxor Corporation (NASDAQ-DXR)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Daxor Corporation (NASDAQ-DXR) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Daxor Corporation (NASDAQ-DXR) Stock FAQ

Data-supported answers about Daxor Corporation (NASDAQ-DXR), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$13.46
Estimated upside 19.8%
Valuation Rating
Undervalued
Estimated upside of 19.8%
Analyst Target
$20
Implied upside 78.1%
Financial Health
Good
Current financial-health read

The current fair value estimate for Daxor Corporation (NASDAQ-DXR) is $13.46. This implies an estimated upside of 19.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 19.8% versus the current market price.

The available analyst price target for Daxor Corporation (NASDAQ-DXR) is $20. The analyst target implies estimated upside of 78.1%.

The current financial health read for Daxor Corporation (NASDAQ-DXR) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Daxor Corporation (NASDAQ-DXR) is November 12, 2026.

The latest available data indicates no current dividend yield for Daxor Corporation (NASDAQ-DXR).

The current P/E ratio listed for Daxor Corporation (NASDAQ-DXR) is 10.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Daxor Corporation is 65.563 M.

The current enterprise value listed for Daxor Corporation is 14.038 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Daxor Corporation is NASDAQ-DXR, and the stock is listed on NASDAQ.

Daxor Corporation (NASDAQ-DXR) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Daxor Corporation is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Daxor Corporation is 49.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 179.4 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 142 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 116.1 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 105.5 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 65.099 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 51.173 B
BDX NYSE Becton Dickinson and Co Fair Value Undervalued Market Cap 49.847 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 44.185 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 41.084 B
DXCM NASDAQ DexCom Inc Fair Value Undervalued Market Cap 33.785 B
RMD NYSE ResMed Inc Fair Value Undervalued Market Cap 31.756 B
ALC NYSE Alcon AG Fair Value Undervalued Market Cap 31.674 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Undervalued Market Cap 29.933 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Undervalued Market Cap 24.452 B
STE NYSE STERIS plc Fair Value Undervalued Market Cap 20.357 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Undervalued Market Cap 17.926 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 15.107 B
PEN NYSE Penumbra Inc Fair Value Fair Market Cap 12.581 B
BAX NYSE Baxter International Inc Fair Value Fair Market Cap 12.242 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 11.566 B